Bio-Layer Interferometry (BLI)

Bio-Layer Interferometry (BLI) is a label-free, real-time optical technique used to measure biomolecular interactions. It provides critical information on the kinetics and affinity of interactions. The technology involves dipping a fiber-optic biosensor into a sample and monitoring changes in light interference as molecules bind to or dissociate from the sensor's surface. Due to its ease of use and high throughput, BLI is now widely used in drug discovery, process development, and QC.

(While the analyte doesn't need a label, the ligand often requires biotinylation (for Streptavidin sensors) or a His-tag/Fc-tag for capture.)

• Legacy: Traditional methods like ELISA were used to measure binding, but they provide only an endpoint measurement, are not real-time, and often require labels that can interfere with the interaction.
• Current Standard: BLI and Surface Plasmon Resonance (SPR) are the two dominant platforms for label-free, real-time interaction analysis. BLI is often favored for its higher throughput and compatibility with crude samples, while SPR generally offers higher sensitivity for very small ligands and very fast kinetics.
• Future: The technology is evolving with the development of more sensitive biosensors, more sophisticated data analysis models, and greater integration into fully automated, high-throughput screening and QC workflows.

The BLI measurement process is elegant and based on optical interference. 

• Immobilization: A "ligand" molecule (e.g., a target protein) is attached to the surface of a fiber-optic biosensor tip.
• Baseline: White light is sent down the fiber. It reflects from two surfaces: an internal reference layer and the outer surface where the ligand is immobilized. The reflected light waves interfere, creating a specific spectral pattern. A stable baseline is established in a buffer.
• Association: The sensor is dipped into a sample containing the "analyte" (e.g., a therapeutic antibody). As the analyte binds to the immobilized ligand, the thickness of the biological layer on the sensor tip increases.
• Wavelength Shift: This change in thickness alters the path of the reflected light, causing a shift in the interference pattern. This shift is measured in real-time in nanometers (nm). The rate of the shift reveals the association rate (kₒₙ).
• Dissociation: The sensor is moved back into a buffer. As the analyte unbinds from the ligand, the layer thins, and the interference pattern shifts back toward the baseline. The rate of this decay reveals the dissociation rate (kₒff).
• Analysis: The resulting binding curve (wavelength shift vs. time) is fitted to a kinetic model to calculate kₒₙ, kₒff, and the affinity constant (Kᴅ), where Kᴅ = kₒff / kₒₙ.

• Data Output: The instrument generates a set of binding curves, often called "sensorgrams," which plot the wavelength shift (nm) over time.
• Interpretation: The analyst fits the sensorgrams to an appropriate kinetic model (e.g., a simple 1:1 binding model for straightforward interactions, or more complex models like 2:1 or mass-transport limited models for more challenging systems). The software then calculates the key parameters.
• k_on (on-rate): How quickly the analyte binds to the ligand (units: M⁻¹s⁻¹).
• k_off  (off-rate): How quickly the analyte dissociates from the ligand (units: s⁻¹).
• Kᴅ (Affinity Constant): The overall strength of the binding interaction (units: M). A lower Kᴅ value signifies a stronger binding interaction.

• Label-Free & Real-Time: Provides kinetic data without chemical labels that could alter molecular function.
• High Throughput: Octet systems can analyze 8, 16, or even 96 samples simultaneously depending on the model.
• Crude Sample Compatibility: The dip-and-read format avoids microfluidics, making it tolerant of complex samples like cell culture supernatants.
• User-Friendly: Generally considered easier to learn and operate than SPR.

• Mass Transport Effects: If binding is very fast, the apparent rate may be limited by analyte diffusion to the sensor surface rather than the intrinsic binding kinetics, leading to distorted results unless experimental conditions are optimized. (Increasing the shaking speed (RPM) or lowering the ligand density on the sensor are the standard CMC strategies to mitigate mass transport in BLI.)
• Sensitivity: Typically less sensitive than high-end SPR systems for very small molecules or interactions with extremely fast dissociation rates.
• Non-Specific Binding (NSB): Molecules may bind non-specifically to the sensor surface, requiring careful experimental design and data correction.

When validating BLI as a GMP potency or quantification assay:

• Specificity: Proving the binding signal is due to the specific interaction of interest.
• Precision: Demonstrating that the calculated kinetic or concentration results are repeatable and reproducible.
• Accuracy: For quantification, showing the result is close to the true value. For kinetics, this is often demonstrated by comparing to an orthogonal method or known standards.
• System Suitability: Defining strict acceptance criteria for each run to ensure the assay is performing as expected before accepting sample results. This includes checks on sensor performance, baseline stability, and the performance of positive/negative controls and reference standards. 

Standardization relies on a well-characterized reference material used as a positive control in each experiment to ensure the system is performing as expected. The quality and consistent immobilization of the ligand on the biosensor are critical for generating reproducible data, often requiring the use of a single, qualified batch of ligand for an entire study.

• Monoclonal Antibodies (mAbs): The most common application, used to measure binding to target antigens and Fc receptors.
• Recombinant Proteins: Characterizing interactions with binding partners, receptors, or substrates.
• Vaccines: Analyzing antibody binding kinetics to vaccine antigens to understand the immune response.
• Gene Therapy: Measuring binding of AAV capsid to target cell receptors (e.g., AAVR) as part of potency characterization, or anti-AAV antibody binding for immunogenicity assessment.